[1] 陈国度,江国英,陈栋兴,等.HBV感染和MICA及TLR10基因多态性与原发性肝癌的关联.中华医院感染学杂志,2023,33(7):986-990.
[2] 魏博文,任峥,张亮,等.增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析.实用肝脏病杂志,2022,25(4):603-604.
[3] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等.原发性肝癌的分层筛查与监测指南(2020版).中华肝胆外科杂志,2021,27(1):12-29.
[4] Mao B, Ma J, Duan S, et al. Preoperative classification of primary and metastatic liver cancer via machine learning-based ultrasound radiomics. Eur Radiol, 2021,31(7):4576-4586.
[5] Thawani R, Gao L, Mohinani A, et al. Quantitative DCE-MRI prediction of breast cancer recurrence following neoadjuvant chemotherapy: a preliminary study. BMC Med Imaging, 2022,22(1):182-192.
[6] Liu L, Hu L, Zeng Q, et al. Dynamic contrast-enhanced MRI of nasopharyngeal carcinoma: correlation of quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters with hypoxia-inducible factor 1α expression and tumor grade/stage. Ann Palliat Med, 2021,10(2):2238-2253.
[7] Bhardwaj R, Boruah DK, Gogoi BB, et al. Added-value of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) magnetic resonance imaging in the preoperative assessment of cervical cancer. J Obstet Gynaecol India, 2022,72(4):330-340.
[8] 李志平,张永胜,崔凤,等.动态对比增强磁共振定量参数三维直方图与前列腺癌Gleason评分的相关性.中华老年医学杂志,2022,41(3):296-301.
[9] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版).中华肝脏病杂志,2022,30(4):367-388.
[10] Barsouk A, Thandra KC, Saginala K, et al. Chemical risk factors of primary liver cancer: an update. Hepat Med, 2021,12(1):179-188.
[11] Liu Y, Zheng J, Hao J, et al. Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019. Cancer Med, 2022, 11(5):1310-1323.
[12] Romano F, Chiarelli M, Garancini M, et al. Rethinking theBarcelona clinic liver cancer guidelines: intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol, 2021, 27(21):2784-2794.
[13] Kariyama K, Nouso K, Wakuta A, et al. Treatment of intermediate-stage hepatocellular carcinoma in Japan: position of curative therapies. Liver Cancer, 2020,9(1):41-49.
[14] Keles DK, Evrimler S, Merd N, et al. Endometrial cancer: the role of MRI quantitative assessment in preoperative staging and risk stratification. Acta Radiol, 2022,63(8):1126-1133.
[15] Yan L, Qu J, Li J, et al. Predicting T and Nstaging of resectable gastric cancer according to whole tumor histogram analysis about a non-cartesian k-space acquisition DCE-MRI: a feasibility study. Cancer Manag Res, 2021,13(1):7951-7960.
[16] Bhardwaj R, Boruah DK, Gogoi BB, et al. Added-value of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE-MRI) magnetic resonance imaging in the preoperative assessment of cervical cancer. J Obstet Gynaecol India, 2022,72(4):330-340.
[17] Li H, Gong G, Wang L, et al. The therapeutic utility of combining dynamic contrast-enhanced magnetic resonance imaging with arterial spin labeling in the staging of nasopharyngeal carcinoma. BMC Med Imaging, 2023,23(1):61-69.
[18] He M, Song Y, Li H, et al. Histogram analysis comparison of monoexponential, advanced diffusion-weighted imaging, and dynamic contrast-enhanced MRI for differentiating borderline from malignant epithelial ovarian tumors. J Magn Reson Imaging, 2020,52(1):257-268.
[19] Lai T, Chen X, Yang Z, et al. Quantitative parameters of dynamic contrast-enhanced magnetic resonance imaging to predict lymphovascular invasion and survival outcome in breast cancer. Cancer Imaging, 2022,22(1):61-71.
[20] Zhu Y, Zhou Y, Zhang W, et al. Value of quantitative dynamic contrast-enhanced and diffusion-weighted magnetic resonance imagingin predicting extramural venous invasion in locally advanced gastric cancer and prognostic significance. Quant Imaging Med Surg, 2021,11(1):328-340. |